This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Vaarala, O. Search for Related Content PubMed PubMed Citation Articles by Vaarala, O. Social Bookmarking                         What's this?

Review : Antiphospholipid antibodies and myocardial infarction

Department of Biochemistry, National Public Health Institute, Helsinki, Finland

In prospective studies, increased levels of cardiolipin-biding antibodies and autoantibodies to oxidized low-density lipoprotein (LDL) have been observed in patients with myocardial infarction (MI). These findings suggest that antiphospholipid antibodies may contribute to the development of MI. The 'oxidative-modification hypothesis' in the pathogenesis of atherosclerotic heart disease is based on the oxidation of LDL, its accumulation into arterial wall, and the development of chronic inflammation in the atheroma. Evidence of enhanced lipid peroxidation and its association with antiphospholipid antibodies has been recently reported in SLE patients. There is also epidemiological data showing a remarkably increased risk of MI in SLE. In this review, the role of different types of antiphospholipid antibodies in the development of atherosclerotic heart disease is evaluated with particular attention to their potential pathogenic mechanisms and the possibilities in the prevention of MI associated with antiphospholipid antibodies.

Key Words: antiphospholipid antibodies • oxidized LDL • prothrombin • β2-glycoprotein I • athero sclerosis • myocardial infarction

Lupus, Vol. 7, No. 2 suppl, S132-S134 (1998)
DOI: 10.1177/096120339800700229


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				T. P. Greco, A. M. Conti-Kelly, T. Greco Jr, R. Doyle, E. Matsuura, J. R. Anthony, and L. R. Lopez Newer Antiphospholipid Antibodies Predict Adverse Outcomes in Patients With Acute Coronary Syndrome Am J Clin Pathol, October 1, 2009; 132(4): 613 - 620. [Abstract] [Full Text] [PDF]

				E Matsuura and L. Lopez Autoimmune-mediated atherothrombosis Lupus, October 1, 2008; 17(10): 879 - 888. [Abstract] [PDF]

				S. Sangle and D. D'Cruz Syndrome X (angina pectoris with normal coronary arteries) and myocardial infarction in patients with anti-phospholipid (Hughes) syndrome Lupus, February 1, 2008; 17(2): 83 - 85. [PDF]

				E Matsuura, K Kobayashi, B. Hurley, and L. Lopez Atherogenic Oxidized Low-Density Lipoprotein/{beta}2-Glycoprotein I (oxLDL/{beta}2GPI) Complexes in Patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome Lupus, July 1, 2006; 15(7): 478 - 483. [Abstract] [PDF]

				E Matsuura, K Kobayashi, K Inoue, L R Lopez, and Y Shoenfeld Oxidized LDL/{beta}2-glycoprotein I complexes: new aspects in atherosclerosis Lupus, September 1, 2005; 14(9): 736 - 741. [Abstract] [PDF]

				M I. Kamboh, S. Manzi, H. Mehdi, S. Fitzgerald, D. K Sanghera, L. H Kuller, and C. E Atson Genetic variation in apolipoprotein H ({beta}2-glycoprotein I) affects the occurrence of antiphospholipid antibodies and apolipoprotein H concentrations in systemic lupus erythematosus Lupus, November 1, 1999; 8(9): 742 - 750. [Abstract] [PDF]